专利检索 cpc:"C07K2317/3520130101" 第 1 页

1.

发明公开
MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE 审中-实审

公开(公告)号：EP4388014A1

公开(公告)日：2024-06-26

申请号：EP22765812.7

申请日：2022-08-17

申请人： F. Hoffmann-La Roche AG

发明人： KUENZEL, Christian , LUTZ, Achim , WESSELS, Uwe

IPC分类号： C07K16/42 , C07K16/22 , C07K16/28 , G01N33/53

CPC分类号： C07K2317/5320130101 , C07K2317/52420130101 , C07K2317/52620130101 , C07K16/22 , C07K16/2863 , C07K16/2854 , C07K2317/3520130101 , C07K16/4283 , G01N33/6854

2.

发明公开
VHH-BASED NKP30 BINDERS 审中-实审

公开(公告)号：EP4359437A2

公开(公告)日：2024-05-01

申请号：EP22735874.4

申请日：2022-06-22

申请人： Merck Patent GmbH

发明人： ZIELONKA, Stefan , TOLEIKIS, Lars , KRAH, Simon , PEKAR, Lukas , EVERS, Andreas

IPC分类号： C07K16/28 , A61P35/00

CPC分类号： C07K16/2803 , C07K16/2863 , C07K2317/2220130101 , C07K2317/2420130101 , C07K2317/3120130101 , C07K2317/3520130101 , C07K2317/5520130101 , C07K2317/56920130101 , C07K2317/7120130101 , C07K2317/7320130101 , C07K2317/9220130101 , C07K2317/9420130101 , A61P35/00 , C07K16/2827 , C07K2317/7620130101

3.

发明公开
CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF 审中-实审

公开(公告)号：EP4430079A1

公开(公告)日：2024-09-18

申请号：EP22822802.9

申请日：2022-11-09

申请人： Regeneron Pharmaceuticals, Inc.

发明人： SHEN, Yang , WANG, Bei , AVVARU, Naga Suhasini , LIN, Chia-Yang , MURPHY, Andrew , HERMANN, Aynur , KIM, Jee H.

IPC分类号： C07K16/28 , C07K14/705

CPC分类号： C07K16/2887 , C07K2319/3320130101 , C07K16/2809 , C07K16/2803 , C07K2317/2420130101 , C07K2317/3120130101 , C07K2317/3520130101 , C07K2317/52620130101 , A61K2039/50520130101 , A61P37/06 , C07K2319/7020130101 , C07K2319/3020130101

4.

发明授权
BISPECIFIC TETRAVALENT ANTIBODIES AND METHODS OF MAKING AND USING THEREOF 有权转让

公开(公告)号：EP3237005B1

公开(公告)日：2024-09-18

申请号：EP15874216.3

申请日：2015-12-19

IPC分类号： A61K39/395

CPC分类号： C07K16/32 , A61K2039/50520130101 , C07K2317/3520130101 , C07K2317/6420130101 , C07K2317/7320130101 , C07K2317/73220130101 , C07K2317/9220130101 , C07K2317/9420130101 , A61K47/6849 , A61K47/6851 , C07K16/2863 , C07K2317/3120130101 , C07K16/3015 , A61P35/00 , A61P43/00 , A61K2039/515220130101

5.

发明公开
ASYMMETRIC BISPECIFIC ANTIBODY (UMG2/CD1A-CD3?) FOR THE IMMUNOLOGICAL TREATMENT OF CORTICAL-DERIVED CD1A-EXPRESSING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIAS (T-ALL) 审中-实审

公开(公告)号：EP4426438A1

公开(公告)日：2024-09-11

申请号：EP22800371.1

申请日：2022-10-28

申请人： Università Degli Studi Magna Graecia Catanzaro

发明人： TASSONE, Pierfrancesco , CARACCIOLO, Daniele , DI MARTINO, Maria Teresa , PENSABENE, Licia , TAGLIAFERRI, Pierosandro

IPC分类号： A61P35/02 , C07K16/28

CPC分类号： A61K2039/50520130101 , A61P35/02 , C07K16/2833 , C07K2317/3020130101 , C07K2317/3520130101 , C07K2317/3120130101 , C07K16/2809 , C07K2317/9220130101 , C07K2317/7320130101 , C07K2317/6020130101 , C07K2317/62220130101

6.

发明公开
CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：EP4424376A2

公开(公告)日：2024-09-04

申请号：EP24174651.0

申请日：2016-08-10

申请人： Legend Biotech Ireland Limited

发明人： FAN, Xiaohu , CHOU, Chuan-Chu , ZHUANG, Qiuchuan , WANG, Pingyan , WANG, Lin , YANG, Lei , HAO, Jiaying

IPC分类号： A61P35/00

CPC分类号： C07K16/30 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70575 , C07K14/70578 , C07K14/70596 , C07K16/2896 , C07K2319/0220130101 , C07K2319/0320130101 , C07K2319/2120130101 , C07K2319/3020130101 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/2220130101 , C07K2317/3120130101 , C07K2317/3520130101 , C07K2317/56920130101 , C07K2319/3320130101 , C12N2510/0020130101 , C07K16/2878 , C12N15/62 , A61P35/00 , A61P35/02 , A61P7/00 , C07K14/435 , A61K39/4631 , A61K39/464424 , A61K39/464417 , A61K2239/4820230501 , A61K39/464426 , A61K2239/2920230501 , A61K39/464412 , C12N5/0636 , A61K39/4611

摘要： Provided herewith is a chimeric antigen receptor (CAR) comprising a polypeptide comprising: (a) an extracellular antigen binding domain comprising a first single-domain antibody (sdAb) specifically binding to a first antigen and a second sdAb specifically binding to a second antigen, wherein at least one of the first antigen and the second antigen is BCMA; (b) a transmembrane domain; and (c) an intracellular signaling domain. Further provided herewith is an isolated nucleic acid comprising a nucleic acid sequence encoding the CAR, a vector comprising the isolated nucleic acid, and an engineered immune effector cell comprising the CAR, the isolated nucleic acid, or the vector. Also provided herewith is a pharmaceutical composition comprising the engineered immune effector cell, and the pharmaceutical composition for use in treating cancer.